Skip to main content
Premium Trial:

Request an Annual Quote

Canhelp Genomics Secures NMPA Approval for Pan-Cancer Tissue-Origin Assay, Analysis Software

NEW YORK – Chinese molecular diagnostics company Canhelp Genomics has received approval from China's National Medical Products Administration (NMPA) for its Canhelp-Origin pan-cancer test and companion analysis software.

A PCR-based tissue-of-origin assay, the Canhelp-Origin Test can measure the gene expression pattern of 90 specific markers of tissue samples and classifies 21 major tumor types that cover more than 95 percent of solid tumors by incidence, the company said. According to the NMPA database, the test, which was approved in mid-July, can be applied to formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples.

Hangzhou-based Canhelp Genomics said the Canhelp-Origin Test has been "comprehensively validated" with numerous clinical studies in collaboration with biomedical centers in China, including Beijing Cancer Hospital, Fudan University Shanghai Cancer Center, and others.

"We believe that the NMPA approval is strong proof of our mRNA-based innovations in cancer diagnostics and an important milestone in the strategy of Canhelp Genomics," said Peter Pu, Canhelp Genomics vice president, in an email.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.